medicinal chemistry approaches and challenges
Špela Gubič (Author), Louise Antonia Hendrickx (Author), Žan Toplak (Author), Maša Sterle (Author), Steve Peigneur (Author), Tihomir Tomašić (Author), Luis A. Pardo (Author), Jan Tytgat (Author), Anamarija Zega (Author), Lucija Peterlin-Mašič (Author)

Abstract

The KV1.3 voltage gated potassium ion channel is involved in many physiological processes both at the plasma membrane and in the mitochondria, chiefly in the immune and nervous systems. Therapeutic targeting KV1.3 with specific peptides and small molecule inhibitors shows great potential for treating cancers and autoimmune diseases, such as multiple sclerosis, type I diabetes mellitus, psoriasis, contact dermatitis, rheumatoid arthritis, and myasthenia gravis. However, no KV1.3 targeted compounds have been approved for therapeutic use to date. This review focuses on the presentation of approaches for discovering new KV1.3 peptide and small-molecule inhibitors, and strategies to improve the selectivity of active compounds toward KV1.3. Selectivity of dalatazide (ShK-186), a synthetic derivate of the sea anemone toxin ShK, was achieved by chemical modification and has successfully reached clinical trials as a potential therapeutic for treating autoimmune diseases. Other peptides and small-molecule inhibitors are critically evaluated for their lead-like characteristics and potential for progression into clinical development. Some small-molecule inhibitors with well defined structure-activity relationships have been optimized for selective delivery to mitochondria, and these offer therapeutic potential for the treatment of cancers. This overview of KV1.3 inhibitors and methodologies is designed to provide a good starting point for drug discovery to identify novel effective KV1.3 modulators against this target in the future.

Keywords

KV1.3 channel;design of KV1.3 inhibitors;mitochondrial KV1.3;peptide inhibitors;small-molecule inhibitors;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL FFA - Faculty of Pharmacy
UDC: 615.4:54
COBISS: 61605123 Link will open in a new window
ISSN: 1098-1128
Views: 23
Downloads: 5
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: Farmacevtska kemija;
Type (COBISS): Article
Pages: str. 2423-2473
Volume: 41
Issue: ǂiss. ǂ4
Chronology: 2021
DOI: 10.1002/med.21800
ID: 18220016